Volume 5 Issue 3, Sep 2020

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 5 Issue 3, Sep 2020:
Letter
Bexarotene combined with lapatinib for the treatment of Cushing’s disease: evidence based on drug repositioning and experimental confirmation
Haoying Yu,Shuyue Ren,Jingrong Wang,Tingting Lv,Lan Sun  ORCID: orcid.org/0000-0003-2931-5172 &…Guanhua Du